Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Atrial Fibrillation

Atrial Fibrillation

Part of Cardiac arrhythmias

Subtypes of Atrial Fibrillation

Nonvalvular Atrial Fibrillation 4 Paroxysmal Atrial Fibrillation 4 Persistent Atrial Fibrillation 4 Long-standing persistent atrial fibrillation 1 Nonparoxysmal Atrial Fibrillation 1 Valvular heart disease-associated atrial fibrillation 1

74 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Atrial Fibrillation

323 trials tracked for Atrial Fibrillation: 82 in phase 3 or 4 and 25 with published results. The most-cited published study has 662 citations.

323Trials tracked
82Phase 3 & 4
0Recruiting
25With published results
Phase distribution
Phase 4 35 Phase 3 47 Phase 2 28 Phase 1 2 Other / NA 211
  1. Phase 3 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study) Completed · 662 cited
  2. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 658 cited
  3. Phase 4 PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF) Completed · 475 cited
  4. Phase 4 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT) Completed · 435 cited
  5. Phase 3 Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation Completed · 347 cited
  6. Phase 3 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) Completed · 262 cited
Show 44 more trials
  1. Phase 3 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) Completed · 246 cited
  2. Phase 3 Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation Completed · 231 cited
  3. Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 223 cited
  4. Phase 4 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed · 172 cited
  5. Phase 3 Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy Completed · 124 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 74 cited
  7. Phase 4 Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery Completed · 66 cited
  8. Phase 4 Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation Completed · 63 cited
  9. Phase 4 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed · 45 cited
  10. Phase 3 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed · 30 cited
  11. Phase 3 Study of DU-176b Aged 80 Years or Older Completed · 26 cited
  12. Phase 3 Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) Completed · 24 cited
  13. Phase 4 Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies Completed · 23 cited
  14. Phase 3 Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial) Completed · 18 cited
  15. Phase 4 Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function Completed · 15 cited
  16. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation Completed · 12 cited
  17. Phase 3 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation Completed · 9 cited
  18. Phase 4 Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion Completed · 4 cited
  19. Phase 3 Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Completed
  20. Phase 4 Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Completed
  21. Phase 4 Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation Completed
  22. Phase 4 Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes Completed
  23. Phase 4 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism Completed
  24. Phase 4 SMART China, A Multi-center Clinical Registry Study Completed
  25. Phase 4 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Completed
  26. Phase 4 Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage Completed
  27. Phase 4 Corticosteroid Pulse After Ablation Completed
  28. Phase 4 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation Completed
  29. Phase 4 Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation Completed
  30. Phase 4 Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study). Completed
  31. Phase 4 The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation Completed
  32. Phase 4 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed
  33. Phase 4 Electrophysiologically Guided PAcing Site Selection Study Completed
  34. Phase 4 Concentrations of Amiodarone in Fat Tissue During Chronic Treatment Completed
  35. Phase 4 Prevention of Atrial Fibrillation Following Esophagectomy Completed
  36. Phase 4 The Home INR Study Completed
  37. Phase 4 A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation Completed
  38. Phase 4 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation Completed
  39. Phase 4 MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure Completed
  40. Phase 4 The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock Completed
  41. Phase 4 Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery Completed
  42. Phase 4 Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation Completed
  43. Phase 4 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring Completed
  44. Phase 4 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Completed

Showing the 50 most-cited and recently-updated of 323 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Routine prophylactic left atrial appendage closure did not significantly reduce the incidence of the primary composite endpoint
Cardiology RCT
Routine prophylactic left atrial appendage closure did not significantly reduce the incidence of the primary composite endpoint Routine valve closure did not significantly reduce stroke risk in heart surgery patients
In a randomized trial involving 2118 patients undergoing valve repair or replacement, surgical left atrial appendage occlusion failed to low…
A major surgery trial found that closing a heart chamber did not lower stroke risk compared to standard care for patients getting valve repa…
May 21, 2026
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk
Cardiology Meta-analysis
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk Dabigatran may be safest for brain bleeding risk
This network meta-analysis of 127,267 patients with venous thromboembolism or atrial fibrillation found that all DOACs had lower risk of int…
All blood thinners beat warfarin for brain bleed risk, but dabigatran may be the safest choice.
Frontiers May 19, 2026
OAC monotherapy offers optimal balance for secondary prevention in atrial fibrillation and stroke patients compared to combination strategies
Cardiology Meta-analysis
OAC monotherapy offers optimal balance for secondary prevention in atrial fibrillation and stroke patients compared to combination strategies Taking one blood thinner alone works best for heart and stroke patients compared to mixing medicines
A network meta-analysis of 14,104 patients suggests oral anticoagulant monotherapy is the most favorable strategy for secondary prevention i…
Doctors found that using just one blood thinner is safer and more effective than mixing it with other pills. This approach lowers stroke ris…
May 15, 2026
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF
Cardiology Meta-analysis
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF New Blood Thinners Cut Bleeding Risk For Dialysis Patients
This meta-analysis of observational studies and RCTs compared apixaban or rivaroxaban with vitamin K antagonists in dialysis patients with a…
New blood thinners could save lives for dialysis patients by cutting bleeding and stroke risks while waiting for bigger studies to confirm t…
May 14, 2026
LAAC and DOACs match warfarin for stroke prevention in AF patients
Cardiology Meta-analysis
LAAC and DOACs match warfarin for stroke prevention in AF patients LAAC and DOACs Cut Bleeding Risk Better Than Warfarin
A network meta-analysis of 78,594 AF patients found LAAC and DOACs offered similar protection against ischemic stroke as warfarin, while sig…
New research shows two new options for atrial fibrillation patients lower bleeding risks while keeping stroke protection the same as older d…
medRxiv May 11, 2026
Guideline defines seven core outcomes for traditional Chinese medicine trials in atrial fibrillation
Drug Pipeline Guideline
Guideline defines seven core outcomes for traditional Chinese medicine trials in atrial fibrillation Doctors agree on seven key outcomes for atrial fibrillation trials
This guideline outlines a core outcome set for traditional Chinese medicine trials in atrial fibrillation. Seven outcomes were selected by 1…
A new standard list of seven outcomes will make it easier to compare atrial fibrillation trials and understand what truly matters to patient…
Frontiers May 7, 2026
Sex differences in outcomes after stroke in NVAF with ASCVD: a post hoc analysis
Cardiology RCT
Sex differences in outcomes after stroke in NVAF with ASCVD: a post hoc analysis Women and Men With AFib and Clogged Arteries Share Same Stroke Risk
This post hoc analysis of an RCT included 222 patients with recent ischemic stroke or TIA, NVAF, and ASCVD. No significant sex differences w…
Women and men with AFib and clogged arteries face similar risks for stroke, heart attack, and bleeding over two years.
May 2, 2026
Sacubitril/Valsartan plus RFCA improves rhythm control in hypertensive NPAF patients
Cardiology RCT
Sacubitril/Valsartan plus RFCA improves rhythm control in hypertensive NPAF patients ARNI plus RFCA improves heart rhythm control in hypertension patients
This randomized controlled trial in 240 hypertensive patients with nonparoxysmal atrial fibrillation compared sacubitril/valsartan plus radi…
Adding sacubitril/valsartan to a heart procedure helped more patients stay in normal rhythm and lowered blood pressure markers.
May 2, 2026
Family history, prior arrhythmia, and anterior infarct location independently raise risk of ventricular fibrillation in STEMI patients
Cardiology Meta-analysis
Family history, prior arrhythmia, and anterior infarct location independently raise risk of ventricular fibrillation in STEMI patients Family history and heart attack location raise risk of dangerous heart rhythms in young patients
This meta-analysis of 1807 cases and 2923 controls confirms that family history of sudden death, previous atrial fibrillation, and anterior …
A large study found that family history of sudden death, past atrial fibrillation, and front heart attacks increase the chance of dangerous …
May 2, 2026
ICE-guided trans-septal puncture reduces fluoroscopy time and radiation dose in AF ablation or LAAO procedures
Cardiology Meta-analysis
ICE-guided trans-septal puncture reduces fluoroscopy time and radiation dose in AF ablation or LAAO procedures New imaging tool cuts radiation and time for heart rhythm patients
This systematic review and meta-analysis evaluated patients undergoing atrial fibrillation ablation or left atrial appendage occlusion.
A large review shows using intracardiac echocardiography during heart procedures reduces radiation exposure and fluoroscopy time without inc…
May 1, 2026
Systematic review and meta-analysis shows adjunctive SVCI reduces AF recurrence but increases minor complications in AF ablation
Cardiology Meta-analysis
Systematic review and meta-analysis shows adjunctive SVCI reduces AF recurrence but increases minor complications in AF ablation Adding SVCI to AF ablation lowers recurrence but raises minor complication risk
This systematic review and meta-analysis of randomized trials evaluated adjunctive superior vena cava isolation (SVCI) plus pulmonary vein i…
A meta-analysis of trials found that adding superior vena cava isolation to standard ablation reduced rhythm recurrence in adults, though mi…
May 1, 2026
Meta-analysis shows VOM ethanol infusion improves sinus rhythm maintenance in persistent AF ablation
Cardiology Meta-analysis
Meta-analysis shows VOM ethanol infusion improves sinus rhythm maintenance in persistent AF ablation Ethanol infusion improves rhythm control in persistent AF
This meta-analysis evaluated VOM ethanol infusion versus PVI with or without linear ablation in patients undergoing catheter ablation for pe…
Adding ethanol to standard ablation helps more people with persistent AF stay in sinus rhythm during the first year.
May 1, 2026

Research across Cardiac arrhythmias

Related studies from across the Cardiac arrhythmias family.

SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
Cardiology Sys. Review
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Frontiers Jun 9, 2026
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults
Cardiology RCT
Memantine reduced PAC burden and new-onset AF in a Phase 2 randomized trial of 241 adults Common Heart Flutters May Be Linked to Brain Drug
In this Phase 2 randomized, double-blind, placebo-controlled trial of 241 symptomatic adults with frequent PACs (≥1000/24 h), memantine show…
A new study shows a brain medication may calm frequent heart flutters and lower the risk of more serious heart rhythm problems.
Apr 22, 2026
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation
Cardiology RCT
Bipolar linear PFA shows similar safety to RFA for CTI ablation in persistent atrial fibrillation PFA Ablation Matches Old Method With Less Time
This substudy RCT compared bipolar linear pulsed field ablation (PFA) with irrigated radiofrequency ablation (RFA) in 141 patients with pers…
Doctors can treat a specific heart rhythm problem faster with new technology without making it less safe.
Apr 16, 2026

Questions about Atrial Fibrillation

Does adding superior vena cava isolation reduce atrial fibrillation recurrence but increase minor complications during ablation?

Yes, adding superior vena cava isolation to standard ablation reduces atrial fibrillation recurrence but increases minor complications like phrenic nerve injury.

Full answer →
Can taking SGLT2 inhibitors help reduce the chance of atrial arrhythmia coming back after catheter ablation?

Yes, SGLT2 inhibitors may reduce the chance of atrial arrhythmia returning after catheter ablation, especially in patients with heart failure.

Full answer →